On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

United Therapeutics has already garnered global attention for its trailblazing work in the organ manufacturing arena. But the FDA’s new clearance propels the business closer to potentially ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

The research offers hope to tens of thousands of patients with kidney failure who are on a long waiting list for an organ ...

The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively.

United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has ...

an experimental but potentially groundbreaking innovation for thousands of Americans on the waiting list for organ transplants. United Therapeutics Corp. said Tuesday that its trial will start ...

United Therapeutics' clinical trial represents a significant advancement in addressing the organ shortage crisis and improving the survival and quality of life for ESRD patients. With a P/E ratio ...